Company ProfilePremium

CUROCOM Co., Ltd.

Company Profile Analysis

주식회사 크레오에스지

ESOMAR 23 Corporate BadgeISO Certifications Badge
CUROCOM Co., Ltd. - Company showcase

Year Founded & Workforce

1997

45 Employees

CUROCOM Co., Ltd. logo

CUROCOM Co., Ltd. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

CUROCOM Co., Ltd. Overview

CreoSG is a micro-cap KOSDAQ company that combines a long-standing but small core-banking software business with an early-stage vaccine and immuno-oncology research programme. The solutions division implements and maintains BANCS-K, a core banking package used by Korean banks and card companies, and accounted for substantially all reported product revenue in FY2025 (KRW 10.86 bn consolidated revenue). The biotechnology division, absorbed through the 2024 merger of subsidiary Immunovax Bio (formerly Sumagen), owns the recombinant vesicular stomatitis virus (rVSV) vector platform SUV-MAP and the whole-killed HIV vaccine candidate SAV001, which completed a US Phase 1 trial and has been in Phase 2 preparation since 2024. The company has reported operating losses in every year from FY2021 to FY2025, has relied on rights offerings, convertible bonds and capital reductions to sustain equity, and sits inside a complex QCP Group cross-shareholding structure with material related-party lending.


Company's own description

Company-provided summaries reproduced by data vendors (WiseReport, 3-Sep-2026; FnGuide; StockDigging) describe CreoSG as a company founded in 1997 for software development and biotechnology, listed on KOSDAQ in 2002, which strengthened its solutions business through a 2005 merger and added real-estate operations in 2024. It reports three activity areas:

  1. Solutions business: supply, implementation and consulting of the BANCS-K core banking package (framework and core account-processing functions) for financial institutions and public bodies; system migration; extension of financial-sector experience into manufacturing and service clients.

  2. Bio business: development of vaccines for infectious diseases (AIDS, COVID-19 and others) using a proprietary general-purpose development platform (SUV-MAP), and, since 2024, immuno-oncology research.

  3. Real-estate operation and rental management: conducted by subsidiary Creo Estate (크레오에스테이트), established April 2024.

A legacy distribution line (computers, monitors, SSDs, printers, peripherals) remains in the description but is immaterial: AlphaSquare's revenue-mix table (FY2025) shows software development and maintenance at 99.7% and computer/peripheral distribution at 0.3%.

Business model and revenue model

Revenue typeBusinessCharacterisationEvidence
Project/implementation revenueSolutionsFixed-scope SI projects for banks (core-banking build, migration, enhancement)H1 2026 growth attributed to new projects for Woori Bank, Hana Bank, National Forestry Cooperative Federation (WiseReport, 3-Sep-2026)
Maintenance (recurring service)SolutionsOngoing maintenance of installed BANCS-K systems"S/W development and maintenance" line, 99.7% of FY2025 mix (AlphaSquare)
Subcontract IT infrastructureSolutionsInfrastructure supply under prime contractorsKRW 1.99 bn Samsung SDS contract, May-2026 to Aug-2027 (TopStarNews, May-2026)
Licensing / milestonesBioNone reported to date; management targets technology transfer after Phase 2Asiae, 15-Oct-2024 and 8-Sep-2026
Product sales (health functional food)Bio-adjacentMUSCLO (CAF-based) supply agreements announced 2025; revenue contribution not separately disclosedAsiae, 14-Mar-2025
Rental incomeReal estateCreo Estate operation and rental managementStockDigging; WiseReport

A Saramin profile displays a "business-segment weighting" of Solutions 67.9%, Bio 20.4%, Other 12.5%; the basis (revenue, headcount or assets) and period are not stated, so it should not be read as a confirmed revenue split.

Value-chain position, customers and end-markets

Solutions: CreoSG is a package-software vendor and implementer positioned below large Korean system integrators (it also acts as a subcontractor to Samsung SDS). A May-2026 Pinpoint News article states the company supplies core-banking solutions to 14 domestic banks and 3 credit-card companies; this figure is not confirmed in a primary filing reviewed.

Bio: CreoSG is a discovery and early-clinical developer that outsources manufacturing (Naobios, France, BSL-3 CDMO), clinical operations (Fortrea, CRO) and preclinical studies (International Vaccine Institute, Gyeongbuk Institute for Bio Industry), consistent with the CEO's statement in September 2026 that the company relies on external infrastructure rather than building its own (Asiae, 8-Sep-2026).

End-markets: Korean banking IT (domestic); infectious-disease vaccines (global public-health purchasers and governments); oncology (global pharma partners); health functional foods (Korea, Southeast Asia, China, Japan).

Independent characterisation

On the evidence, CreoSG is functionally a small, loss-making Korean banking-software contractor (revenue around KRW 11–12 bn on a trailing basis) carrying an early-stage biotech option. The bio business generates no disclosed licensing revenue, and its flagship asset has been "preparing for Phase 2" since at least April 2024. Reported net losses have been driven as much by non-operating items (equity-method losses, CB valuation changes, related-party financial exposures) as by operations. The equity story depends on capital-market access and on group-level financing arrangements with Curo Holdings and GNCO.

Strategy

Stated strategy themes

Bio-centred restructuring (Mar-2024): rename to CreoSG; move bio programmes (SUV-MAP, HIV vaccine) under the listed parent to speed commercialisation and ease partnerships with leading biotech companies (Edaily, 29-Mar-2024).

Platform expansion from vaccines into immuno-oncology: use SUV-MAP as an oncolytic vector, alone and in combination with tumour-matrix-loosening technology; pursue co-development or licensing with multinational pharma (Asiae, 8-Sep-2026).

Market-led clinical prioritisation: move vaccine candidates with existing markets (Hantavirus, SFTS) into clinical trials to generate revenue (CEO, Asiae, 8-Sep-2026).

Geographic targeting: MERS (Saudi Arabia, Middle East, Southeast Asia), Zika (Brazil), Ebola (Africa, Europe) (CEO, Asiae, 8-Sep-2026).

Asset-light R&D: rely on IVI, universities, national R&D programmes and CDMOs/CROs until profitability (CEO, Asiae, 8-Sep-2026).

Monetisation of bio assets: in Oct-2025 the company said it was pursuing an overseas sale of bio business assets, including Sumagen Canada (Asiae, 1-Oct-2025).

Solutions: extend financial-sector experience to manufacturing and service clients; system migration (FnGuide summary).

Initiatives in the last 24 months

DateInitiativeStatus / outcomeSource
Apr-2024Creo Estate real-estate subsidiaryOperatingSaramin
Apr-2024Naobios manufacturing contract for SAV001 Phase 2In production as of Oct-2025Asiae
Jul–Sep-2024Absorption of Immunovax BioCompleted Sep-2024Asiae; Saramin
Aug–Oct-2024Immuno-oncology team and research centreTeam head hired; centre build reportedAsiae
Sep–Nov-2024KRW 30 bn rights offeringCompletedAsiae
Nov-2024 / Oct-2025Alteogen MOU and MTAJoint formulation research ongoingAsiae
Dec-2024 / Mar-2025CAF/MUSCLO health-food businessDistribution agreements announced; revenue targets not met in FY2025Asiae
H1-2025KRW 10 bn third-party offeringFailedAsiae, 1-Oct-2025
Oct-2025 / Mar-2026Capital reduction and share consolidationCompleted (relisted 12-May-2026)Asiae; Datatooza
Apr–Aug-2026Review of CB acquisition and management participation in OCP Bio MTerminated 31-Aug-2026 after the valuation report was not issued and due diligence found material negative financial conditionsGoInsider (DART summary)
Jun-2026KDCA Marburg vaccine projectParticipatingAsiae
Oct-2026Debt-to-equity swap into Curo HoldingsExpected closing 23-Oct-2026Digital Today

Sustainability/ESG commitments and cost programmes

None publicly disclosed in sources reviewed.

Medium-term financial targets / guidance

The company has not issued formal financial guidance. The only quantified targets found are the March-2025 MUSCLO revenue targets (KRW 10 bn in 2025, KRW 80 bn in 2026, KRW 120 bn in 2027, KRW 200 bn+ per year from 2028), stated in a press article rather than a regulatory filing (Asiae, 14-Mar-2025). FY2025 reported consolidated revenue (KRW 10.86 bn, 99.7% software) indicates the 2025 target was not achieved.

Products & Services

Solutions segment

OfferingDescriptionTarget customerLaunch / statusPricing modelSource
BANCS-K (Banking Automation & Network Control System – Korea)Core banking package providing framework and core account-processing functions; described by the company as applied at Korean financial institutions for more than 15 yearsBanks, card companies, cooperative financial institutions, public bodiesIn market since at least the mid-2000sProject + maintenance fees (not disclosed)JobKorea profile; AlphaSquare
System migrationMigration of legacy banking systemsFinancial institutionsOngoingProject-basedFnGuide business summary
SI / SM / DB constructionSystem integration, system management and maintenance, database buildFinancial, manufacturing and service clientsOngoingProject / time-and-materialsSaramin profile
IT consulting (IT strategy, ISP, corporate growth strategy)Consulting from strategy through solution deliveryEnterprisesDescribed as "recently started" in JobKorea profile—JobKorea profile
IT infrastructure supplyInfrastructure supply under Samsung SDS prime contract, KRW 1.99 bn, 26-May-2026 to 25-Aug-2027 (18.32% of FY2025 revenue)Samsung SDS (prime contractor)2,026Contract valueTopStarNews, May-2026
Computer and peripheral distributionLED/TV monitors, SSDs, PCs, laptops, printers, MFPs, scannersCorporate buyersLegacy; 0.3% of FY2025 revenueResale marginInvesting.com; Saramin

Independent note: The name "BANCS" matches the core-banking product line originally developed by Australia's Financial Network Services and later owned by Tata Consultancy Services (TCS BaNCS). The 2005 merger with "FnS.com" suggests a historical link, but the licensing relationship between CreoSG and TCS is not confirmed in the sources reviewed.

Bio segment — platform

AssetDescriptionStatusSource
SUV-MAP (Sumagen rVSV Multifunctional All Platform)Attenuated recombinant vesicular stomatitis virus vector. Target-antigen genes are inserted into the vector and the recombinant virus is grown in cell culture. The company says it can identify a vaccine candidate within about 5 months of obtaining viral information and reach GMP production within about 6 months. Designed to be temperature-sensitive so replication is limited in humans. Interferon-suppression function weakened for oncology use.Platform launched 2024; EPO grant Oct-2024 (valid in 17 EU unitary-patent states); company states patents in more than 10 countriesAsiae, 29-Jul-2024, 22-Oct-2024, 23-Oct-2024, 8-Sep-2026

Bio segment — pipeline (product by product)

CandidateIndicationTechnologyStage (latest disclosed)PartnersKey disclosed data / eventsSource
SAV001 / SAV001-HHIV/AIDS (therapeutic and preventive intent)Whole-killed HIV vaccine (chemically and radiation inactivated)Phase 1 completed in US (4 California hospitals, HIV subtype B carriers); Phase 2 clinical material in production; FDA Type C meeting agreement on Phase 2 synopsisNaobios (CDMO, France), Fortrea (CRO), Dr. Onesmo Mpanju (former FDA CBER reviewer, consultant)Antibody titres rose up to 512-fold and were maintained for 12 months in Phase 1 per company; COVID-19 interrupted CMO capacity; production "progressing" as of Oct-2025Asiae, 22-Apr-2024, 28-Aug-2024, 15-Oct-2024, 13-Oct-2025
SUV-MAP HIV boost (combination regimen)HIV/AIDSSAV001 prime + VSV-vector boostEfficacy evaluation (preclinical)—Announced May-2024Asiae, 9-May-2024
VSV-MERSMERS-CoVSUV-MAP with MERS spike/envelope proteinPreclinical; patents: Korea (decision 1-Sep-2025), Saudi Arabia (Mar-2026), Canada (Jun-2026)IVI; University of Western Ontario (Prof. Kang Chil-yong)Company is planning a commercialisation roadmap; Middle East and Southeast Asian interest cited by CEOAsiae, 1-Sep-2025, 24-Mar-2026, 26-Jun-2026, 8-Sep-2026
VSV-ZikaZika virusSUV-MAP with Zika envelope proteinPreclinical; Korean patent registered Mar-2025IVIBrazil interest cited by CEOAsiae, 1-Sep-2025, 8-Sep-2026
VSV-COVID-19SARS-CoV-2SUV-MAPPreclinical (first SUV-MAP vaccine; animal efficacy reported superior to comparators by company)IVI; Gyeongbuk Vaccine Commercialisation CenterPatents obtained per companyAsiae, 23-Oct-2024
SFTS + HFRS bivalent vaccineSevere fever with thrombocytopenia syndrome and haemorrhagic fever with renal syndrome (Hantavirus)SUV-MAPCandidate identified under national project; CEO targets clinical entryGyeongbuk Institute for Bio Industry national project; IVICompany describes it as the first bivalent candidate for both diseasesAsiae, 29-Jul-2024, 4-Sep-2024, 8-Sep-2026
VSV-Ebola (Zaire)EbolaSUV-MAP with Ebola glycoproteinCandidate secured (preclinical)—Announced 11-Aug-2026Asiae, 11-Aug-2026
VSV-MarburgMarburg virus diseaseAttenuated recombinant VSVCo-research institution in KDCA project for candidate and assay developmentKorea Disease Control and Prevention Agency (KDCA)Announced 2-Jun-2026Asiae, 2-Jun-2026
Crimean-Congo haemorrhagic fever, Nipah, LassaHigh-risk emerging infectionsSUV-MAPPlanned/early research—Listed as expansion targetsThe Bell, 6-Aug-2026; Asiae, 22-Oct-2024
Rotavirus and dengue vaccinesRotavirus, dengueAI-based protein design + SUV-MAPEarly research—Announced in Sep-2026 interviewAsiae, 8-Sep-2026
SUV-MAP oncolytic immunotherapySolid tumours (breast, colorectal, pancreatic, skin targeted)Interferon-sensitive VSV vector that replicates selectively in tumour cells; cytokine-gene payloads; combination with tumour-matrix-loosening technologyMechanism-of-action confirmation and candidate optimisation (preclinical)Alteogen (ALT-B4 hyaluronidase; MOU Nov-2024, MTA 2-Oct-2025)In-house immuno-oncology research centre built 2024Asiae, 6-Nov-2024, 29-Oct-2024, 2-Oct-2025, 8-Sep-2026
Inferrex antibioticDrug-resistant S. aureus ("superbug")Small-molecule/antibiotic (details not disclosed)Research; Japanese patent——AlphaSquare; WiseReport

Health functional foods (bio-adjacent)

ProductDescriptionPartnersStatusSource
MUSCLO (머슬로)Muscle-growth drink and powder based on CAF (Cell Activation Factor), derived from brown-algae polyphenol Seapolynol; company states CAF obtained US FDA New Dietary Ingredient notificationHepatol (rights holder; MOU Dec-2024 and supply agreement); Human Cell Medical (Southeast Asia), Shandong SC Technology Innovation (China), Elumild (Japan)Company announced Asian distribution start in Mar-2025 with targets of KRW 10 bn revenue in 2025, KRW 80 bn in 2026, KRW 120 bn in 2027 and KRW 200 bn+ annually from 2028Asiae, 27-Dec-2024 and 14-Mar-2025

Analyst note: Total consolidated FY2025 revenue was KRW 10.86 bn, with 99.7% attributed to software. The MUSCLO revenue targets were therefore not met in FY2025, and no MUSCLO revenue line is visible in disclosed data.

Financial Narrative

Accounting basis: K-IFRS consolidated. FY2024 and FY2025 figures use final (audited) values reproduced by AlphaSquare and Hankyung Korea Market. Preliminary disclosures differed:

Income statement (chartable)

Sources and methods: FY2022–FY2025 revenue, operating income and net income from AlphaSquare (DART). FY2021 revenue derived from FY2022 revenue and Hankyung's reported FY2022 growth of 13.27%; FY2021 operating and net income derived from Hankyung's FY2021 margins (-52.62%, -190.57%). Gross profit FY2021–FY2023 from Hankyung (reported in KRW mn); FY2024–FY2025 derived from Hankyung gross margins. EBITDA FY2025 from WiseReport. EPS FY2021–FY2024 from Hankyung on the pre-consolidation basis (par KRW 500); FY2025 EPS from WiseReport on the current basis. The restated EPS row multiplies pre-2025 values by 10 to reflect the 2:1 and 5:1 consolidations (derived; approximate). Diluted EPS: not disclosed in sources reviewed. Dividends: none paid (Simply Wall St).

Margins and growth (chartable)

Source: Hankyung Korea Market financial summary (FY2021–FY2025). EBITDA margin FY2025 derived (-5.840 / 10.861).

Revenue CAGR FY2021–FY2025: approximately 5.9% per year (derived: (10.861 / 8.635)^(1/4) − 1). The growth is not steady: two of the four years show declines, and FY2025 recovered from a weak FY2024 base.

Recent quarters (chartable)

Source: AlphaSquare (DART quarterly data). Q1 FY2026 also confirmed by AWAKEPLUS (revenue KRW 2.6 bn, operating loss KRW 0.8 bn, net loss KRW 1.9 bn; quarterly report filed 15-May-2026).

Trailing four quarters to 30-Jun-2026 (derived): revenue KRW 11.912 bn; operating loss KRW -3.807 bn; net loss KRW -3.175 bn.

H1 FY2026 vs H1 FY2025 (WiseReport, 3-Sep-2026): revenue +22.1%; operating loss reduced 73.3%; net loss reduced 97.9%. H1 FY2026 revenue was KRW 5.812 bn (derived from Q1 + Q2) against approximately KRW 4.76 bn in H1 FY2025 (AKGround, citing the H1 FY2025 report). H1 FY2025 operating loss was KRW -3.55 bn (same source).

Balance sheet (chartable)

Sources and methods: Total assets FY2024–FY2025 from the 13-Feb-2026 DART results disclosure (Digital Today/Nate). FY2025 total equity of KRW 47.214 bn from the "own capital" figure in the 15-Oct-2026 DART acquisition disclosure; equity attributable to owners and share capital from the 13-Feb-2026 disclosure. FY2024 share capital of about KRW 97.6 bn and impairment ratio of 47.7% from Asiae, 1-Oct-2025; FY2024 equity derived as capital × (1 − 0.477) (approximate). Liabilities derived as assets minus equity. BPS from Hankyung (FY2021–FY2024) and WiseReport (FY2025). Goodwill and intangibles, short/long-term debt split, net debt and working capital: not publicly disclosed in sources reviewed. A data vendor (AlphaSpread) reports total debt of KRW 25.06 bn at the latest reporting date, without stating the date or composition.

Latest balance sheet (H1 FY2026, AlphaSquare): total assets KRW 91.396 bn; liabilities 47.98% and equity 52.02% of assets (implying equity of about KRW 47.55 bn and liabilities of about KRW 43.85 bn, derived).

Cash flow (chartable)

Cash-flow statements were not available in the sources reviewed. Dividends: none (Simply Wall St). Treasury shares: 40,120 (0.20%) as of 28-Sep-2026 (WiseReport); no buyback programme found.

Ratios (chartable)

Sources: ROE and debt ratio FY2025 from AlphaSquare (FnGuide shows ROE of -29.01% on a different, likely trailing, basis). ROA and asset turnover FY2025 derived using average FY2024–FY2025 total assets (KRW 90.12 bn). P/B from Hankyung. ROIC, current ratio, interest coverage and cash conversion cycle: not publicly disclosed in sources reviewed; interest coverage is not meaningful because operating income is negative in every year.

Commentary on trends, inflections and drivers

Revenue. Revenue sat between KRW 8.2 bn and KRW 9.8 bn from FY2021 to FY2024. The FY2024 decline (-16.4%) was attributed by the company to lower solutions revenue (Datatooza, 12-Feb-2025). The FY2025 rebound (+33.2%) was attributed to higher revenue in the solutions division and subsidiaries (13-Feb-2026 disclosure). H1 FY2026 growth (+22.1%) came from new projects with Woori Bank, Hana Bank and the National Forestry Cooperative Federation (WiseReport). The business is project-driven, so quarterly revenue moves with contract timing.

Gross margin. Gross margin improved from 23.8% (FY2022) to 34.8% (FY2025). The disclosed data does not explain the cause; a higher maintenance share or better project pricing are possible explanations but are not confirmed.

Operating losses. Operating losses have been large relative to revenue in every year (margins between -38% and -69%). The FY2024 widening was attributed to development costs for producing Phase 2 HIV-vaccine clinical material (Datatooza, 12-Feb-2025). Because pre-Phase 3 development costs must be expensed, the merger of Immunovax Bio in 2024 moved these costs directly into CreoSG's income statement and reduced equity (Asiae, 1-Oct-2025). The sharp narrowing of the Q2 FY2026 operating loss to KRW -0.14 bn is the main inflection in the data. Whether it reflects lower bio spending (for example, timing of Naobios production payments) or solutions operating leverage is not disclosed.

Net losses. Net losses exceeded operating losses by KRW 7–12 bn per year from FY2021 to FY2024, which indicates large non-operating charges. The FY2025 improvement was attributed to valuation gains on convertible bonds held by the company and smaller equity-method losses (13-Feb-2026 disclosure). Q2 FY2026 showed a net profit of KRW 1.78 bn despite an operating loss, again pointing to non-operating gains; the composition is not disclosed in the sources reviewed. These items are tied to the group's cross-holdings and CB instruments and are not recurring operating earnings.

Capital structure. Equity has been maintained through repeated issuance (rights offerings, third-party allotments, CBs) and two share consolidations. The capital-impairment ratio rose to 53.0% at H1 FY2025 and triggered an "investment caution" designation. The 2:1 capital reduction cut share capital from about KRW 97.6 bn to KRW 48.8 bn and used the reduction to offset accumulated deficits, bringing the impairment ratio to 5.14% at FY2025 year-end. This is an accounting remedy; it did not add cash.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentContentsKey products/servicesNotes

Solutions

Core-banking package sales, SI, SM, IT consulting, legacy hardware distribution

BANCS-K; system migration; IT strategy/ISP consulting

Majority of revenue; H1 2026 growth driver

Bio

Vaccine and immuno-oncology R&D (in-house since 2024 merger) plus subsidiaries Sumagen Canada and Inferrex

SUV-MAP platform; SAV001; MERS, Zika, SFTS/HFRS, COVID-19, Ebola, Marburg candidates; oncolytic VSV

No disclosed licensing revenue

Real estate (Other)

Creo Estate (est. Apr-2024)

Property operation and rental management

Revenue not separately disclosed

Revenue by Segment

SegmentFY2023FY2024FY2025

Total consolidated revenue (KRW Bn)

9.7568.15710.861

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Product Lines

Product lineShare of revenue (%)

Software development and maintenance (Solutions)

99.7

Computers and peripherals (Distribution)

0.3

Group Entities

EntityRelationshipActivitySource

Sumagen Canada Inc.

Consolidated subsidiary

Overseas vaccine R&D; MERS patent holder in Canada

WiseReport; The Bell, 6-Aug-2026

Inferrex

Consolidated subsidiary

Antibiotic research for drug-resistant bacteria; Japanese patent on S. aureus therapy

WiseReport; AlphaSquare

Creo Estate (크레오에스테이트)

Consolidated subsidiary

Real estate operation

WiseReport; Saramin

GNCO Co., Ltd. (지엔코, KOSDAQ 065060)

Investee; CreoSG stake 46.29% after Sep-2025 CB call-option exercise; 37.70% shown in a May-2026 holding record

Fashion apparel

Digital Today, 17-Sep-2025; GoInsider

Curo Holdings Co., Ltd. (KOSDAQ 051780)

Largest shareholder of CreoSG; CreoSG holds 9.96%, rising to 36.85% on completion of the Oct-2026 debt-to-equity swap

Coffee distribution; group holding

IB Tomato, 1-Jul-2026; Digital Today, 15-Oct-2026

Q Capital Partners (KOSDAQ 016600)

Affiliate; holds 3.96% of CreoSG (Aug-2026) and is a lender to Curo Holdings

Venture capital

GoInsider; IB Tomato

K Partners (케이파트너스)

Second-largest shareholder of CreoSG (2024–2025); owner-family vehicle

Holding

Asiae, 1-Oct-2025; Etoday, 19-Aug-2026

Financial Analysis

ItemPreliminary disclosureFinal (used below)Source

FY2024 operating loss (KRW Bn)

-5.610-5.654

Datatooza/Edaily, 12-Feb-2025; AlphaSquare

FY2024 net loss (KRW Bn)

-13.024-13.879

Same

FY2025 operating loss (KRW Bn)

-6.099-6.409

Digital Today/Nate, 13-Feb-2026; AlphaSquare

FY2025 net loss (KRW Bn)

-8.467-8.550

Same

Income Statement and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (KRW Bn)

8.6359.7819.7568.15710.861

Gross profit (KRW Bn)

2.7152.3312.4012.5043.776

Operating income (KRW Bn)

-4.544-6.139-3.735-5.654-6.409

EBITDA (KRW Bn)

————-5.840

Net income (KRW Bn)

-16.456-13.061-13.494-13.879-8.550

EPS basic, as reported (KRW)

-118-83-93-83-441

EPS basic, restated to current share basis (KRW)

-1,180-830-930-830-441

Dividends per share (KRW)

00000

Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue growth YoY (%)

-12.0213.27-0.26-16.3933.15

Gross margin (%)

31.4323.8324.6130.7034.77

Operating margin (%)

-52.62-62.77-38.28-69.31-59.01

EBITDA margin (%)

————-53.77

Net margin (%)

-190.57-133.53-138.31-170.14-78.72

Income Statement

MetricQ3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026

Revenue (KRW Bn)

2.8863.2142.6313.181

Operating income (KRW Bn)

-0.922-1.936-0.812-0.137

Net income (KRW Bn)

-0.909-2.146-1.9041.784

Balance Sheet and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Total assets (KRW Bn)

———91.50388.742

Total equity incl. NCI (KRW Bn)

———51.05047.214

Equity attributable to owners (KRW Bn)

————46.292

Total liabilities (KRW Bn)

———40.45341.528

Share capital (KRW Bn)

———97.60148.801

Capital impairment ratio (%)

———47.75.14

BPS as reported (KRW)

379.82306.83251.56261.402,430

BPS restated to current share basis (KRW)

3,7983,0682,5162,6142,430

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Analysis (Annual)

MetricFY2021FY2022FY2023FY2024FY2025

Dividends paid (KRW Bn)

00000

Instrument by Date

DateInstrumentAmountTermsSource

Nov-2024

Shareholder rights offering (planned KRW 30 bn, 41 mn shares at expected KRW 732)

—

Final price implied at about KRW 538 by the group's subscription (derived: 7.5 bn / 13,949,238 shares)

Asiae, 4-Sep-2024 and 7-Nov-2024

H1 2025

Third-party offering (planned KRW 10 bn)

Not completed (investors withdrew/changed)

—

Asiae, 1-Oct-2025

Sep-2025

Small public offering to K Partners

KRW 0.99999995 bn

Subscription 15-Sep, payment 19-Sep-2025; 6-month lock-up

Digital Today, 3-Sep-2025

Nov-2025

Private CB (23rd series, inferred numbering)

KRW 2.0 bn

0% coupon; 8% YTM (quarterly compounding); KRW 0.968 bn working capital, KRW 1.032 bn debt repayment

Edaily, Nov-2025

May-2026

24th private CB

—

0% coupon; for working capital

GoInsider (DART summaries 18/22-May-2026)

Jul-2026

CB conversion

335,664 shares at KRW 3,575 (about KRW 1.2 bn, derived)

Listed 21-Jul-2026

TopStarNews, Jul-2026

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2021FY2023FY2024FY2025

ROE (%)

———-17.46

ROA (%)

———-9.49

Debt ratio, liabilities/equity (%)

———88.33

Asset turnover (x)

———0.12

Price / book at year-end (x)

2.982.052.17—

Revenue by Region

RegionFY2023FY2024FY2025

Total revenue (KRW Bn)

9.7568.15710.861

Capital Markets

ItemValueSource

Close

KRW 2,975

AlphaSquare

52-week range (adjusted)

KRW 2,780–12,800 (note: an intraday low of KRW 2,720 was printed on 19-Oct-2026, so the displayed low appears to use closing prices or lag)

AlphaSquare

Market cap

KRW 59.1 bn (derived)

Derived

Shares outstanding

19,856,196

TopStarNews

Daily volume (19-Oct-2026)

39,224 shares

AlphaSquare

Short interest

0 shares (15-Oct-2026)

AlphaSquare

Beta (1-year)

0.61 (FnGuide, earlier period)

FnGuide

Dividend history and policy

No recent dividends

Simply Wall St

Buyback authorisations

None found; 40,120 treasury shares

WiseReport

Credit ratings (Moody's/S&P/Fitch)

Not rated

—

Korean agency ratings

None found

—

Capital Markets Data (KRW)

MetricJun-2026Jul-2026Aug-2026Sep-2026Oct-2026

Reference close (KRW)

8,0008,7406,4603,4152,975

Valuation Multiples

MultipleCreoSGBasis

P/S

4.96x

Market cap / trailing revenue KRW 11.91 bn

P/B

1.22x

FY2025 BPS KRW 2,430 (WiseReport); AlphaSquare displays 2.01x on its own basis

EV/Sales

Not computed

Cash balance not disclosed

Capital Instruments

InstrumentIssuedAmountKey termsStatusSource

20th CB

Aug-2021

———

Saramin

21st CB

Mar-2022

———

Saramin

22nd CB

Aug-2023 (dated by sequence)

———

Saramin

23rd CB (numbering inferred)

Nov-2025

KRW 2.0 bn

0% coupon; 8% YTM

Partly converted (335,664 shares at KRW 3,575, Jul-2026)

Edaily; TopStarNews

24th CB

May-2026

—

0% coupon; private

Outstanding

GoInsider

Total debt (latest report)

—

KRW 25.06 bn

Composition not stated

—

AlphaSpread

Analyst Conclusions

Management guidance

No formal financial guidance. Management's qualitative priorities (Asiae, 8-Sep-2026): start SAV001 Phase 2 once clinical material is complete; move Hantavirus and SFTS vaccine candidates into clinical trials; develop oncolytic SUV-MAP to a stand-alone candidate and seek partners; pursue overseas markets for MERS, Zika and Ebola vaccines; build in-house capacity only after profitability.

Consensus

No sell-side coverage; no consensus estimates.

Bull case

  1. Solutions momentum may reach break-even. Revenue grew 33.15% in FY2025 and 22.1% in H1 FY2026, and the Q2 FY2026 operating loss narrowed to KRW 0.14 bn. A full year near operating break-even would remove the main source of equity erosion.

  2. SAV001 is a differentiated clinical asset. Phase 1 data (company-reported antibody increases maintained for 12 months), an FDA-agreed Phase 2 synopsis and engaged CDMO/CRO partners mean a Phase 2 start is plausible; any licensing deal would be large relative to a KRW 59 bn market cap.

  3. Platform IP and public funding. Granted patents in Europe, Korea, Saudi Arabia and Canada, plus KDCA and IVI collaborations, give SUV-MAP credibility for government-funded programmes with low capital needs.

Bear case

  1. Related-party exposure dominates the balance sheet risk. KRW 9.15 bn of loans to the controlling shareholder were partly converted into KRW 8.09 bn of illiquid parent equity (17.14% of CreoSG's equity), deepening a circular structure that already includes GNCO.

  2. Funding dependence and dilution. A failed KRW 10 bn offering, a KRW 1 bn related-party top-up, recurring CBs and two share consolidations show that capital is scarce; Phase 2 HIV trials would require more.

  3. Credibility gap. The MUSCLO revenue targets were not met, SAV001 Phase 2 has been "imminent" since 2024, the OCP Bio M initiative was reversed, and an unfaithful-disclosure designation was reported.

Catalysts and monitorables (next 12 months)

Catalyst / monitorableExpected timingWhy it matters
Closing of Curo Holdings debt-to-equity swap23-Oct-2026Size of related-party exposure; voting-rights questions
Q3 FY2026 reportMid-Nov-2026Whether Q2's narrower operating loss is sustained
SAV001 Phase 2 IND filing / first patientNot datedPrimary bio re-rating event
FY2025-type annual results for FY2026Feb–Mar 2027Capital-impairment test; going-concern language
New CB issuance or conversionsOngoingDilution
Pledge enforcement or largest-shareholder change filingsOngoingControl stability
Bio-asset sale (Sumagen Canada)Not datedPossible non-dilutive cash
New bank core-system contractsOngoingSolutions revenue visibility

Concluding analyst verdict

CreoSG is two businesses joined to a group-financing structure. The first is a small but real Korean core-banking software and services operation that grew revenue to KRW 10.86 bn in FY2025 and kept growing in H1 FY2026, with improving gross margins and a sharply narrower Q2 FY2026 operating loss. On its own, that business would be a modest, project-driven contractor worth roughly what the market currently pays, and the data suggests it is moving towards operating break-even.

The second is a biotechnology option built around the SUV-MAP rVSV platform and the SAV001 whole-killed HIV vaccine. The scientific assets have genuine elements, including completed Phase 1 work, granted patents across several jurisdictions, and collaborations with IVI, KDCA, Alteogen, Naobios and Fortrea. But the flagship programme has been in Phase 2 preparation for more than two years without a disclosed start date, the pipeline is broad relative to resources, and the health-food targets publicised in 2025 were not realised.

The decisive factor for an investor is governance and capital allocation. Losses have been absorbed through rights offerings, convertible bonds, a capital reduction and a share consolidation, while the listed company has lent money to its controlling shareholder and is now converting KRW 8.09 bn of that lending into a 36.85% stake in the same shareholder. Pledged shares, a reported unfaithful-disclosure designation and a reversed acquisition review add to the concern. These features make reported net income, book value and even control of the company less reliable than the headline numbers imply.

Verdict: CreoSG is a high-risk, speculative micro-cap. Operating improvement in the solutions business is a positive, but it is outweighed by related-party financial exposure, dependence on dilutive financing and the absence of a dated clinical catalyst. Any engagement should be conditioned on audited FY2026 results, clarity on the Curo Holdings transaction and a confirmed SAV001 Phase 2 start.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenureBackgroundCompensationSource

Dr. Lee Sang-gyun (이상균)

CEO and representative director

Since Mar-2024

Led bio research at subsidiary Sumagen for many years; developer of SUV-MAP

Not disclosed (Korean rules require individual disclosure only above KRW 500 mn)

Edaily, 29-Mar-2024; Inews24, 29-Mar-2024

Dr. Son Ho-seon (손호선)

Head of immuno-oncology R&D

Since Aug-2024

BS/MS Seoul National University; PhD in developmental and neuroendocrinology; LG Chem drug-discovery team (CDK4 inhibitor); KCDC vaccine research division from 2011 (smallpox vaccine)

—

Asiae, 19-Aug-2024

Joong-Ki Cho; Jong-Sung Park

Listed as key executives

Titles not disclosed

——

PatSnap company profile

“—” = not publicly disclosed.

Governance Overview

ItemDetailSource

Outside directors

2 (both attended board meetings on 10-Apr-2026 and 15-Oct-2026)

Digital Today, 10-Apr-2026 and 15-Oct-2026

Audit function

"Auditor (audit committee member)" attended board meetings; whether a statutory auditor or an audit committee is used is not clear from the summaries

Same

Major Shareholders

HolderSharesStake (%)DateSource

Curo Holdings and 7 related parties (total)

8,274,73941.67

28-Sep-2026

WiseReport

of which Curo Holdings

15,818,348 (pre-consolidation count)

20.26

16-Apr-2026

GoInsider

of which GNCO

5,589,204 (pre-consolidation count)

7.16

16-Apr-2026

GoInsider

of which Q Capital Partners

—3.96

6-Aug-2026

GoInsider

of which Dr. Lee Sang-gyun (CEO)

—0.67

13-Aug-2026

GoInsider

Treasury shares

40,1200.20

28-Sep-2026

WiseReport

Foreign investors

—0.00

Oct-2026

AlphaSquare

Competitive Landscape

Key Competitors

CompetitorPositioning vs CreoSG

Samsung SDS

Large SI prime contractor; also a CreoSG customer (May-2026 contract)

LG CNS

Major financial-sector SI

SK AX (formerly SK C&C)

Major SI with financial practice

Bankware Global (KOSDAQ)

Korean core-banking package vendor; most direct domestic package competitor

TmaxSoft / Tmax group

Banking frameworks and middleware

Tata Consultancy Services (TCS BaNCS)

Global core-banking package (same product heritage as BANCS)

Oracle (FLEXCUBE)

Global core-banking package

Temenos

Global core-banking package

Infosys (Finacle)

Global core-banking package

Merck & Co.

Holds an approved rVSV-vector Ebola (Zaire) vaccine, the main validation of the rVSV approach

IAVI and Public Health Vaccines

rVSV candidates for Lassa, Marburg, Sudan ebolavirus and Nipah

Moderna

mRNA platform competing for rapid-response vaccine programmes

SK bioscience; EuBiologics; GC Biopharma

Korean vaccine developers/manufacturers competing for government programmes

Competitor Detail

MetricCreoSG

Revenue, latest FY

KRW 10.86 bn (FY2025)

Revenue growth

33.15% (FY2025)

Operating margin

-59.01% (FY2025)

Company Snapshot

$7.6M

Revenue

45

Employees

1997

Founded

SWOT Analysis

Strengths

  • Revenue recovery in solutions: FY2025 revenue +33.15% to KRW 10.86 bn and H1 FY2026 +22.1%, driven by Woori Bank, Hana Bank and NFCF projects (DART via Digital Today; WiseReport).
  • Improving gross margin: 23.83% (FY2022) to 34.77% (FY2025) (Hankyung).
  • Clinical-stage HIV asset: SAV001 completed US Phase 1 with reported up-to-512-fold antibody increases maintained 12 months, and an FDA Type C meeting agreement on the Phase 2 synopsis (Asiae, 22-Apr-2024, 15-Oct-2024).
  • Granted IP across jurisdictions: EPO platform patent (Oct-2024), Korean Zika and MERS patents (2025), Saudi and Canadian MERS patents (2026) (Asiae).
  • Credible external collaborators: IVI since 2018, KDCA Marburg project (Jun-2026), Alteogen MTA (Oct-2025), Naobios and Fortrea (Asiae).
  • Blue-chip solutions customers: Samsung SDS KRW 1.99 bn contract equal to 18.32% of FY2025 revenue (TopStarNews).

Weaknesses

  • Persistent losses: operating losses every year FY2021–FY2025, with margins from -38% to -69% (Hankyung).
  • Net losses well above operating losses: e.g., FY2024 net loss KRW 13.88 bn vs operating loss KRW 5.65 bn, driven by non-operating items (AlphaSquare).
  • Repeated capital-impairment events: impairment ratio 47.7% (FY2024) and 53.0% (H1 FY2025), cured by a capital reduction rather than new capital (Asiae, 1-Oct-2025).
  • Failed financing: KRW 10 bn offering not completed in H1 2025; only KRW 1.0 bn raised from a related party in Sep-2025 (Asiae).
  • Missed commercial targets: MUSCLO targeted KRW 10 bn revenue in 2025, but FY2025 revenue was 99.7% software (Asiae, 14-Mar-2025; AlphaSquare).
  • Small scale: about 45–65 employees (Saramin; JobKorea); ranked 94th of 100 KOSDAQ IT-services companies by revenue (AlphaSquare).

Opportunities

  • SAV001 Phase 2 start could re-rate the bio business if it begins in the US/Canada as planned with Fortrea (Asiae, 13-Oct-2025).
  • Government pandemic-preparedness funding: KDCA Marburg project (Jun-2026) and earlier national projects for SFTS/HFRS (Asiae).
  • MERS commercialisation in the Middle East supported by the Saudi patent (Mar-2026) and stated Saudi interest (Asiae, 8-Sep-2026).
  • Oncology partnering: CEO is pursuing co-development or licensing of oncolytic SUV-MAP with multinational pharma (Asiae, 8-Sep-2026).
  • Asset monetisation: stated plan to sell bio assets, including Sumagen Canada, abroad (Asiae, 1-Oct-2025).
  • Korean bank IT replacement cycle: new 2026 projects with major banks (WiseReport).

Threats

  • Related-party credit exposure: KRW 9.15 bn of loans to Curo Holdings (Apr-2026), now partly converted into KRW 8.09 bn of parent equity (Digital Today).
  • Control instability from pledged shares: pledges by Curo Holdings that could change the largest shareholder (Dealsite, 26-Nov-2024; DART correction 17-Sep-2026).
  • Dilution: successive CBs (20th–24th series) and a 335,664-share conversion in Jul-2026 (Saramin; TopStarNews).
  • Disclosure-quality penalties: unfaithful-disclosure designation reported in an Etoday digest (2026) and the reversed OCP Bio M initiative (GoInsider).
  • Competition from larger platforms: approved rVSV Ebola vaccine (Merck) and mRNA players compete for the same government budgets.
  • Share-price volatility: trading around KRW 8,000–9,400 in Jun–Jul-2026 fell to KRW 2,975 by 19-Oct-2026 (Asiae price boxes; AlphaSquare), complicating equity-funded R&D.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
H1-2025Planned KRW 10 bn third-party capital increase not completed after investors withdrew or changed terms Asiae, 1-Oct-2025Failed financing; deepened capital impairment
Aug-2025 (H1 report)Capital impairment ratio reported at 53.0% at 30-Jun-2025; designated an "investment caution" issue Asiae, 1-Oct-2025Raised risk of administrative-issue designation
1-Sep-2025Korean patent registration decision for SUV-MAP MERS vaccine (co-developed with IVI) AsiaeIP progress
3-Sep-2025KRW 1.0 bn small public offering to K Partners decided Digital TodayMinimal capital support from related party
10/17-Sep-2025CB call option exercised; GNCO stake rises to 46.29% Digital TodayDeepened cross-holding
1-Oct-20252-for-1 capital reduction decided; capital from about KRW 97.6 bn to KRW 48.8 bn to offset deficits AsiaeAvoided administrative-issue designation
2-Oct-2025Material Transfer Agreement with Alteogen AsiaeImmuno-oncology collaboration step
13-Oct-2025Update: SAV001 Phase 2 material production with Naobios progressing; Fortrea engaged AsiaeClinical timeline still undated
Nov-2025Execution of reduction
Nov-2025KRW 2.0 bn private CB (0% coupon, 8% YTM) EdailyShort-term financing, partly to repay debt
13-Feb-2026FY2025 results: revenue +33.15% to KRW 10.86 bn; operating loss KRW 6.10 bn (preliminary); net loss KRW 8.47 bn; capital impairment 5.14% Digital Today/NateRevenue recovery; loss narrowed at net level
16-Mar-20265-for-1 share consolidation decided (97,602,661 to 19,520,532 shares) Edaily; FETVShare-count reset
24-Mar-2026MERS vaccine patent in Saudi Arabia AsiaeIP in a key MERS market
31-Mar-2026AGM (planned) to approve consolidation FETVApproved (consolidation executed)
9-Apr-2026Trading halt notice from 14-Apr-2026 for consolidation Edaily; DatatoozaLiquidity interruption
10-Apr-2026KRW 6.33 bn loan to largest shareholder Curo Holdings (6%, to 9-Apr-2029); total loans KRW 9.15 bn Digital TodayMaterial related-party exposure
17-Apr-2026MOU with OCP Bio M on CB acquisition and management participation GoInsiderLater abandoned
12-May-2026Consolidated shares relisted DatatoozaTrading resumed
15-May-2026Q1 FY2026 report: revenue KRW 2.6 bn, operating loss KRW 0.8 bn, net loss KRW 1.9 bn AWAKEPLUSContinued losses
18/22-May-202624th private CB decided and issued (0% coupon) GoInsiderFurther dilution potential
May-2026KRW 1.99 bn IT infrastructure contract with Samsung SDS (to Aug-2027) TopStarNews18.3% of FY2025 revenue
2-Jun-2026Joins KDCA Marburg vaccine project AsiaeGovernment validation of platform
8-Jun-2026KRX inquiry on sharp share-price movement GoInsiderSpeculative trading
26-Jun-2026MERS vaccine patent in Canada AsiaeIP progress
1-Jul-2026Press report details Curo Holdings' KRW 11.25 bn borrowing from CreoSG and pledges of CreoSG shares IB TomatoGovernance scrutiny
21-Jul-2026335,664 shares listed from CB conversion at KRW 3,575; total shares 19,856,196 TopStarNewsDilution
6-Aug-2026SUV-MAP global patent portfolio announcement Asiae; The BellIP messaging
7-Aug-2026Inquiry answer: OCP Bio M review ongoing, nothing confirmed GoInsider—
11-Aug-2026Zaire Ebola vaccine candidate announced AsiaePipeline breadth
14-Aug-2026H1 FY2026 report: Q2 revenue KRW 3.18 bn, Q2 net profit KRW 1.78 bn GoInsider; AlphaSquareFirst quarterly net profit in the period reviewed
19-Aug-2026Press report on QCP Group succession via K Partners EtodayGroup governance
20-Aug-2026Press coverage linking CreoSG's platform to Moderna's late-stage cancer-vaccine news Asiae (headline)Sector read-across, not company data
–Listed among companies designated "unfaithful disclosure corporations" in an Etoday disclosure digest Etoday digest–
31-Aug-2026OCP Bio M investment review terminated; separate inquiry answer states no material undisclosed information GoInsider; AWAKEPLUSReversal of a disclosed initiative
8-Sep-2026CEO interview on immuno-oncology and vaccine commercialisation plans AsiaeStrategy clarity; no new data
17-Sep-2026Correction to share-pledge contract disclosure involving change of largest shareholder GoInsiderControl risk
15-Oct-2026KRW 8.09 bn debt-to-equity swap into Curo Holdings (stake to 36.85%), closing 23-Oct-2026 Digital Today; Special TimesCircular holding deepened; loan converted to illiquid equity

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

2 charts
Revenue by Segment: Total consolidated revenue rose from KRW 9,756 Mn in FY2023 to KRW 10,861 Mn in FY2025.
CUROCOM Co., Ltd. — Revenue by Segment
Series (KRW Mn)FY2023FY2024FY2025
Total consolidated revenue9,7568,15710,861

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Edaily — name change to CreoSG (29-Mar-2024) (edaily.co.kr)
  2. Hankyung — name change and bio restructuring (29-Mar-2024) (hankyung.com)
  3. Inews24 — name change (29-Mar-2024) (inews24.com)
  4. Yakup — name change (28-Mar-2024 AGM) (m.yakup.com)
  5. Digital Gangnam Culture Encyclopedia — corporate history (gangnam.grandculture.net)
  6. Saramin — company profile and history (saramin.co.kr)
  7. Saramin (mobile) — 2026 history items (m.saramin.co.kr)
  8. JobKorea — company profile (m.jobkorea.co.kr)
  9. WiseReport — company overview, shareholders, H1 2026 commentary (comp.wisereport.co.kr)
  10. AlphaSquare — prices, financials, quarterly data (alphasquare.co.kr)
  11. Hankyung Korea Market — financial ratios FY2021–FY2025 (markets.hankyung.com)
  12. FnGuide — business summary (comp.fnguide.com)
  13. ChickStock — revenue and operating income FY2022–FY2025 (chickstockfi.com)
  14. Edaily — FY2024 results (edaily.co.kr)
  15. Datatooza — FY2024 results and drivers (datatooza.com)
  16. Nate/Digital Today — FY2025 results (m.news.nate.com)
  17. AKGround — H1 FY2025 figures (akground.com)
  18. AWAKEPLUS — Q1 FY2026 report (awakeplus.co.kr)
  19. Asiae CORE — capital reduction (1-Oct-2025) (core.asiae.co.kr)
  20. Edaily — share consolidation decision (16-Mar-2026) (edaily.co.kr)
  21. FETV — share consolidation and segments (fetv.co.kr)
  22. Datatooza — trading resumption (11-May-2026) (datatooza.com)
  23. TopStarNews — capital-reduction trading halt (topstarnews.net)
  24. TopStarNews — CB-conversion additional listing (topstarnews.net)
  25. TopStarNews — Samsung SDS contract (topstarnews.net)
  26. Edaily — KRW 2.0 bn CB (edaily.co.kr)
  27. Digital Today — KRW 1.0 bn offering (3-Sep-2025) (digitaltoday.co.kr)
  28. Digital Today — GNCO stake increase (digitaltoday.co.kr)
  29. Digital Today — loan to Curo Holdings (10-Apr-2026) (digitaltoday.co.kr)
  30. Digital Today — Curo Holdings share acquisition (15-Oct-2026) (digitaltoday.co.kr)
  31. Special Times — Curo Holdings share acquisition filing (specialtimes.co.kr)
  32. GoInsider — disclosures, holdings, pledges (goinsider.kr)
  33. IB Tomato / Daum — Curo Holdings borrowings (v.daum.net)
  34. Toyo Economy — Curo Holdings debt-to-equity offering (sateconomy.co.kr)
  35. Dealsite — share pledge disclosure (26-Nov-2024) (dealsite.co.kr)
  36. Etoday — company news digest (incl. disclosure designation listing) (etoday.co.kr)
  37. Asiae CORE — CEO interview (8-Sep-2026) (core.asiae.co.kr)
  38. Asiae CORE — SAV001 Phase 2 material (13-Oct-2025) (core.asiae.co.kr)
  39. Asiae CORE — Naobios contract (16-Apr-2024) (core.asiae.co.kr)
  40. Asiae CORE — Phase 1 antibody data (22-Apr-2024) (core.asiae.co.kr)
  41. Asiae CORE — Phase 2 production test (15-Oct-2024) (core.asiae.co.kr)
  42. Asiae CORE — CEO profile (23-Oct-2024) (core.asiae.co.kr)
  43. Asiae CORE — merger approval (29-Jul-2024) (core.asiae.co.kr)
  44. Asiae CORE — KRW 30 bn rights offering (4-Sep-2024) (core.asiae.co.kr)
  45. Asiae CORE — largest-shareholder subscription (7-Nov-2024) (core.asiae.co.kr)
  46. Asiae CORE — Alteogen MOU (6-Nov-2024) (core.asiae.co.kr)
  47. Asiae — Alteogen MTA (2-Oct-2025) (view.asiae.co.kr)
  48. Asiae CORE — EPO patent (22-Oct-2024) (core.asiae.co.kr)
  49. Asiae — MERS Korean patent (1-Sep-2025) (view.asiae.co.kr)
  50. Asiae CORE — MERS Saudi patent (24-Mar-2026) (core.asiae.co.kr)
  51. Asiae CORE — MERS Canada patent (26-Jun-2026) (core.asiae.co.kr)
  52. Asiae — KDCA Marburg project (2-Jun-2026) (view.asiae.co.kr)
  53. Asiae CORE — SUV-MAP patent portfolio (6-Aug-2026) (core.asiae.co.kr)
  54. The Bell / Money Today — SUV-MAP patent portfolio (mt.co.kr)
  55. Asiae CORE — Ebola candidate (11-Aug-2026) (core.asiae.co.kr)
  56. Asiae CORE — IVI collaboration (28-May-2024) (core.asiae.co.kr)
  57. Asiae CORE — immuno-oncology hire (19-Aug-2024) (core.asiae.co.kr)
  58. Asiae CORE — immuno-oncology centre (29-Oct-2024) (core.asiae.co.kr)
  59. Asiae CORE — Hepatol MOU (18-Dec-2024) (core.asiae.co.kr)
  60. Asiae CORE — MUSCLO rights (27-Dec-2024) (core.asiae.co.kr)
  61. Asiae CORE — MUSCLO launch and targets (14-Mar-2025) (core.asiae.co.kr)
  62. Asiae CORE — HIV vaccine market data (11-Apr-2024) (core.asiae.co.kr)
  63. Pinpoint News — BANCS-K customer base (pinpointnews.co.kr)
  64. StockDigging — company summary (stockdigging.com)
  65. PFlowMoney — daily prices (Aug-2026) (pflowmoney.com)
  66. Investing.com — CreoSG quote page (investing.com)
  67. AlphaSpread — solvency and debt (alphaspread.com)
  68. Simply Wall St — dividends (simplywall.st)
  69. PatSnap — company profile (discovery.patsnap.com)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.